Inflammatory bowel disease: Review and future view

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 5, 2012, Pages 1638-1647

  Maher, Maha M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Biomarkers; Crohn's disease; Epidemiology; Inflammatory bowel disease; Management; Review; Ulcerative Colitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BARIUM; BASILIXIMAB; BIOLOGICAL MARKER; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DACLIZUMAB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; NATALIZUMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VISILIZUMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANKYLOSING SPONDYLITIS; ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CAPSULE ENDOSCOPY; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG EFFICACY; ENTERITIS; ESCHERICHIA COLI; FIBEROSCOPE; GRAFT VERSUS HOST REACTION; HEALING; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE MUCOSA; JUVENILE RHEUMATOID ARTHRITIS; LIFESTYLE MODIFICATION; MUCOSAL HEALING; MULTIPLE SCLEROSIS; NONHUMAN; PROGNOSIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSH ENTEROSCOPE; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; UVEORETINITIS; REVIEW;

HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84860853953     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e485     Document Type: Article

References (87)

1. Riis L, Vind I, Politi P, Wolters F, Vermeire S, Tsianos E, Freitas J, Mouzas I, Ruiz Ochoa V, O'Morain C, Odes S, Binder V, Moum B, Stockbrugger, Langholz E, Munkholm P: Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 101, 1539-1545(2006)) (Pubitemid 43982551)
2. Roda G, Caponi A, Benevento M, Nanni P, Mezzanotte L, Belluzzi A, Mayer L, Roda A: New Proteomic Approaches for Biomarker Discovery in Inflammatory Bowel Disease. Inflamm Bowel Dis 16,1239-1246 (2010))
3. Harewood GC, Gostout CJ, Farrell MA, Knipschield MA: Prospective controlled assessment of variable stiffness enteroscopy. Gastrointest Endosc; 58; 267-271(2003)) (Pubitemid 38220284)
4. Hugh James Freeman: Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol 7; 16 (1): 15-20 (2010))
5. Jason K Hou and joseph H Sellin: Diet, nutrition and inflammatory bowel disease. Therapy 7(2), 179-189 (2010))
6. Asakura H, Suzuki K, Kitahora T, Morizane T: Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? J Gastroenterol Hepatol 23,(12):1794-1801(2008))
7. Petros P. Sfikakis: The First Decade of Biologic TNF Antagonists in Clinical Practice: Lessons Learned, Unresolved Issues and Future Directions. Kollias G, Sfikakis PP (eds): TNF Pathophysiology. Molecular and Cellular Mechanisms. Curr Dir Autoimmun. Basel, Karger, 11,180 - 210 (2010))
8. Giacomo L, Giulia R, Andrea B, Enrico R, Gian P B: Inflammatory bowel disease: Moving toward a stem cell-based therapy. World J Gastroenterol 7,14(29): 4616-4626 (2008))
9. D. scott Wilson, G Dalmasso, L Wang, S V Sitaraman, D Merlin, N Murthy: Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nature Materials 9,923- 928(2010))
10. Molinie F, Gower-Rousseau C, Yzet T, Merle V, Grandbastien B, Marti R, Lerebours E, Dupas J- L, Colombel J-F, Salomez J-L: Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut 53,843-848 (2004)) (Pubitemid 38662134)
11. Lakatos L, Mester G, Erdelyi Z, Balogh M, Szipocs I, Kamaras G, Lakatos PL: Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 10,404-409 (2004)) (Pubitemid 38208096)
12. Yapp TR, Stenson R, Thomas GA, Lawrie BW, Williams GT, Hawthorne AB: Crohn's disease incidence in Cardiff from 1930: an update for 1991-1995. Eur J Gastroenterol Hepatol 12 (8),907-11 (2000)) (Pubitemid 30663903)
13. Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterol 126,1504-1517 (2004)) (Pubitemid 38649869)
14. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK: An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 103,3167-3182 (2008))
15. Severine V, Gert V A& Paul R: Role of biomarkers in the diagnosis of inflammatory bowel disease. Expert Opin Med Diagn 1(4),481-488 (2007))
16. Canani RB, Romano MT, Greco L, Terrin G, Sferlazzas C, Barabino A, Fontana M, Roggero P, Guariso G, De Angelis G, Fecarotta S, Polito G, Cucchiara S: Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: implications for diagnosis and follow-up of children with Crohn's disease. Inflamm Bowel Dis 10,234-239 (2004)) (Pubitemid 38618252)
17. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A: Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol;99:2235- 2241(2004)) (Pubitemid 39524716)
18. Xuhang Li, Laurie Conklin, Philip Alex: New serological biomarkers of inflammatory bowel disease. Wor J Gastroenterol; 7 14(33): 5115-5124 (2008))
19. Li X, Conklin L, Alex P: New serological biomarkers of inflammatory bowel disease. World J Gastroenterol 14,5115-5124 (2008))
20. Felley-Bosco E, André M: Proteomics and chronic inflammatory bowel diseases. Pathol Res Pract 200,129- 133 (2004)) (Pubitemid 38950442)
21. Hardwdige PR, Rodriguez-Escudero I, Goode D, Donohoe S, Eng J, Goodlett DR, Aebersold R, Finaly BB: Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli. J Biol Chem 279,20127-20136 (2004)) (Pubitemid 38623457)
22. Harewood GC, Gostout CJ, Farrell MA, Knipschield MA: Prospective controlled assessment of variable stiffness enteroscopy. Gastrointest Endosc 58, 267-271(2003) (Pubitemid 38220284)
23. Hara A K, Leighton J A, HeighR I, Sharma V K, Silva A C, Petris G, Hentz J G, Fleischer D E: Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel followthrough, and ileoscopy. Radiology 238,128-134 (2006)) (Pubitemid 43010588)
24. Triester SL, Leighton JA, Leontiadis GI: A metaanalysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with nonstricturing small bowel Crohn's disease. Am J Gastroenterol 101, 954-964 (2006)) (Pubitemid 43725307)
25. Solem CA, Loftus EV Jr, Fletcher JG: Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 68, 255-266 (2008)) (Pubitemid 352024383)
26. Eduardo Redondo-Cerezo: Role of wireless capsule endoscopy in inflammatory bowel disease. World J Gastrointest Endosc; 16, 179-185 ( 2010))
27. Akhtar RY, Lewis BS, Ullman T: Mucosal healing of Crohn's disease demonstrated by capsule endoscopy in a woman with obscure gastrointestinal bleeding. Am J Gastroenterol 104,1065-1066 (2009))
28. Cave D, Legnani P, de Franchis R, Lewis BS: ICCE consensus for capsule retention. Endoscopy 37, 1065-1067 (2005)) (Pubitemid 41489290)
29. Lewis BS: Expanding role of capsule endoscopy in inflammatory bowel disease. World J Gastroenterol 14,4137-4141 (2008))
30. Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ: Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 6,1218-24 (2008))
31. Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterol 70,439- 44(1976))
32. Harvey RF, Bradshaw JM: A simple index of Crohn's-disease activity. Lancet 1,514 (1980))
33. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Dobos GJ: Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMNelastase, CRP, and clinical indices. Am J Gastroenterol 103,162-9 (2008))
34. Regueiro M, Schraut WH, Kip K, et al. Silent Crohn's disease (CD): poor correlation between Crohn's Disease Activity Index (CDAI) and endoscopic activity scores one year after intestinal resection and ileocolonic anastamosis [abstract]. Gastroenterol 136, A685 (2009))
35. D'Haens G, Baert F, Van Assche G, Caenepeel P, Verqauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T,van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 371,660-667 (2008)) (Pubitemid 351284485)
36. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63,433-42 (2006)) (Pubitemid 43261469)
37. Shane M Devlin, Remo Panaccione: Evolving Inflammatory Bowel Disease Treatment Paradigms: Top Down Versus Step-Up. Med Clin N Am 94,1-18 (2010).
38. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E: Clinical, biological, and endoscopicpicture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etud Th-erapeutique des Affections Inflammatoires Digestives. Gastroenterol 98,811-8 (1990)) (Pubitemid 20095830)
39. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ: Effect of once- or twice- daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 5,95- 102 (2007)) (Pubitemid 46096842)
40. Zwiers A, Fuss IJ, Leijen S, Mulder CJ, Kraal G, Bouma G: Increased expression of the tight junction molecule claudin-18 A1 in both experimental colitis and ulcerative colitis. Inflamm Bowel Dis 14,1652-1659 (2008))
41. Frey MR, Edelblum KL, Mullane MT, Liang D, Polk DB: The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology 136, 217-226 (2009))
42. Hansen JJ, Holt L, Sartor RB: Gene expression patterns in experimental colitis in IL-10-deficient mice. Inflamm Bowel Dis 15, 890-899 (2009))
43. Kristensen NN, Olsen J, Gad M, Claesson MH: Genomewide expression profiling during protection from colitis by regulatory T cells. Inflamm Bowel Dis 14, 75-87(2008)) (Pubitemid 351196872)
44. Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, Phillips A and Brown MA: Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 41, 1330-1334 (2009))
45. Singh UP, Singh NP, Singh B, Mishra MK, Nagarkatti M, Nagarkatti PS, Singh SR: Stem cells as potential therapeutic targets for inflammatory bowel Disease. Front Biosci (Schol Ed) 1,2:933-1008 (2010))
46. Hanauer SB: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12, S3-9 (2006)) (Pubitemid 43068428)
47. Asakura H, Suzuki K, Kitahora T, Morizane T. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? J Gastroenterol Hepatol 23(12),1794-1801 (2008))
48. Han PD, Burke A, Baldassano RN, Rombeau JL and Lichtenstein GR: Nutrition and inflammatory bowel disease. Gastroenterol Clin 28,423-436 (1999)
49. FG Campos, DL Waitzberg, MG Teixeira, DR Mucerino, DR Kiss, A Habr-Gama: Pharmacological Nutrition in Inflammatory Bowel Diseases. Nutr Hosp XVIII (2) 57-64 (2003))
50. Russel MG, Engels LG, Muris JW, Limonard CB, Volovics A, Brummer RJ, Stockbrugger RW: 'Modern life' in the epidemiology of inflammatory bowel disease: a case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol 10(3), 243-249 (1998). (Pubitemid 28175002)
51. Hart AR: Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis - a European prospective cohort study. Gut 58, 1577-1579 (2009).
52. Razack R, Seidner DL: Nutrition in inflammatory bowel disease. Curr Opin Gastroenterol 23(4),400- 405(2007)) (Pubitemid 46878952)
53. Shah S: Dietary factors in the modulation of inflammatory bowel disease activity. Med Gen Med 9(1), 60 (2007))
54. Riordan AM, Ruxton CH, Hunter JO: A review of associations between Crohn's disease and consumption of sugars. Eur J Clin Nutr 52(4), 229-238 (1998)) (Pubitemid 28159617)
55. Bernstein CN, Leslie WD, Leboff MS: AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124(3), 795-841 (2003)) (Pubitemid 36268496)
56. McClain C, Soutor C, Zieve L: Zinc deficiency: a complication of Crohn's disease. Gastroenterol 78(2), 272- 279 (1980)) (Pubitemid 10128498)
57. Aslan, A. and Triadafilopoulos, G: Fish oil fatty acid supplementation in active ulcerative colitis: a doubleblind, placebo-controlled, crossover study. Am J Gastroenterol 87: 432-437(1992))
58. Seidner DL, Lashner BA, Brzezinski A, Banks PC, Goldblum J, Fiocchi C, Katz J, Lichtenstein GR, Anton PA, Kam LY, Garleb KA, Demichele SJ: An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol 3, 358-369 (2005)) (Pubitemid 40488344)
59. Rahimi R, Mozaffari S, Abdollahi M: On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci. 54(3),471-480 (2009))
60. Singh S, Aggarwal BB: Activation of transcription factor NFκkB is suppressed by curcumin (diferuloylmethane). J Biol Chem 270 (42), 24995-25000 (1995))
61. Hennessee O, Cook W: Aloe Myth, Magic and Medicine: Aloe Vera Across Time. Universal Graphics, PA, USA (1989))
62. Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A, Jewell DP, Rampton DS: Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment.Pharmacol Ther19(7), 739-747 (2004)) (Pubitemid 38496639)
63. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, Buller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AW Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterol 131(1),117-129 (2006)) (Pubitemid 44015753)
64. Catherine Clinton: Plant tannins: A novel approach to the treatment of ulcerative colitis. Natural Medicine Journal 1(3), (2009))
65. D'Arienzo A, Manguso F, Astarita C, D'Armiento FP, Scarpa R, Gargano D, Scaglione G, Vicinanza G, Bennato R, Mazzacca G:Allergy and mucosal eosinophil infiltrate in ulcerative colitis. Scand J Gastroenterol 35(6),624-631 (2000)) (Pubitemid 30441714)
66. Mazzon E, Muià C, Paola RD, Genovese T, Meneqazzi M, De Sarro A, Suzuki H, Cuzzocrea S: Green tea polyphenol extract attenuates colon injury induced by experimental colitis. Free Radic Res 39(9),1017 (2005))
67. Petros P. Sfikakis: The First Decade of Biologic TNF Antagonists in Clinical Practice: Lessons Learned, Unresolved Issues and Future Directions. Kollias G, Sfikakis PP (eds): TNF Pathophysiology. Molecular and Cellular Mechanisms. Curr Dir Autoimmun. Basel, Karger, 11,180-210 (2010))
68. Sagar G and Mark A Peppercorn: Ulcerative colitis: current treatment strategies and future prospects. Therap Advan in Gastroenterol 2(2) 99-108 (2009))
69. Hanauer SB: New steroids for IBD: progress report. Gut 51,182-3(2002))
70. Sandborn WJ: New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord;5:10-8 (2005)) (Pubitemid 40443992)
71. Carpenter HA, Talley NJ: The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications. Am J Gastroenterol 95,878-96 (2000)) (Pubitemid 30196720)
72. Plevy S, Salzberg B, Van Assche G, Requeiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J: A phase I study of visilizumab, a humanized anti- CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterol 133,1414-22 (2007)) (Pubitemid 350029746)
73. Tao GZ, Strnad P, Zhou Q, Kamal A, Zhanq L, Madani ND, Kugathasan S, Brant SR, Cho JH, Omary MB, Duerr RH: Analysis of keratin polypeptides 8 and 19 variants in inflammatory bowel disease. Clin Gastroenterol Hepatol 5:857-64 (2007)) (Pubitemid 47039231)
74. Grimm MC: New and emerging therapies for inflammatory bowel diseases. J Gastroenterol Hepatol 24(S3), S69-74 (2009))
75. Julián Panés, Azucena Salas: Mechanisms underlying the beneficial effects of stem cell therapies for inflammatory bowel Diseases. Gut 58, 898 (2009).
76. Barker N, van de Wetering M, Clevers H: The intestinal stem cell. Genes Dev 22,1856-64 (2008)) (Pubitemid 352008634)
77. Van der Flier LG, Clevers H: Stem cells, selfrenewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 71,241-60 (2009))
78. Wang P, Hou SX: Regulation of intestinal stem cells in mammals and Drosophila. J Cell Physiol 222,33-7 (2010))
79. Murry CE, Keller G: Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132:661-80 (2008)) (Pubitemid 351260059)
80. Srivastava AS, Feng Z, Mishra R, Malhotra R, Kim HS, Carrier E: Embryonic stem cells ameliorate piroxicam-induced colitis in IL10-/- KO mice. Biochem Biophys Res Commun 361,953-9 (2007)) (Pubitemid 47259028)
81. Drakos PE, Nagler A, Or R: Case of Crohn's disease in bone marrow transplantation. Am J Hematol 43,57-158 (1993))
82. Craig RM, Traynor A, Oyama Y, Burt RK: Hematopoietic stem cell transplantation for severe Crohn's disease. Bone Marrow Transplant 32,57-59 (2003))
83. Burt RK, Traynor A, Oyama Y, Craig R: High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 101,2064-2066 (2003)) (Pubitemid 36237615)
84. Oyama Y, Craig RM, Traynor AE, Quiqley K, Statkute L, Halverson A, Brush M, Verda L, Kowalska B, Krosnjar N, Krosnjar N, Kletzel M, Whitington PF, Burt RK; Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterol 128,552-563 (2005)) (Pubitemid 40585356)
85. Taupin P: OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr Opin Investig Drugs 7,473-481(2006)) (Pubitemid 43772988)
86. Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, Lanzoni G, Cantoni S, Cavallini C, Bianchi F, Tazzari LP, Pasquinelli G, Foroni L, Ventura C, Grossi A and Bagnara GP: Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol 7, 11 (2007).
87. Brittan M, Alison MR, Schier S, Wright NA: Bone marrow stem cell- mediated regeneration in IBD: where do we go from here? Gastroenterol132,1171- 3(2007))